Skip to main content

Market Overview

Jefferies Downgrades Salix Pharmaceuticals To Hold

Share:

Analysts at Jefferies downgraded Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) from Buy to Hold.

The price target for Salix Pharmaceuticals has been raised from $149.00 to $173.00.

Salix Pharmaceuticals shares have gained 51.17% over the past 52 weeks, while the S&P 500 index has surged 11.47% in the same period.

Salix Pharmaceuticals' shares fell 0.54% to $171.54 in pre-market trading.

Latest Ratings for SLXP

DateFirmActionFromTo
Mar 2015JefferiesDowngradesBuyHold
Feb 2015Cantor FitzgeraldDowngradesBuyHold
Feb 2015UBSDowngradesBuyNeutral

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings

 

Related Articles (SLXP)

View Comments and Join the Discussion!

Posted-In: JefferiesDowngrades Analyst Ratings

Latest Ratings

StockFirmActionPT
NIUDaiwa CapitalInitiates Coverage On41.5
QMCONorthland Capital MarketsInitiates Coverage On12.0
IBKRJefferiesInitiates Coverage On89.0
MRETFTD SecuritiesDowngrades18.5
SWKSGoldman SachsDowngrades135.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com